A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2)

Clinical trial NCT04077437 · COMPLETED

Trial details

NCT number: NCT04077437
Sponsor: Resilient Pharmaceuticals
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Posttraumatic Stress Disorder

Start date: 2020-09-02
Primary completion: 2022-10-30
Enrollment: 121

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.